Pain! Wann gehts wieder nach Norden? - 500 Beiträge pro Seite
eröffnet am 20.08.18 22:19:56 von
neuester Beitrag 16.05.20 02:40:23 von
neuester Beitrag 16.05.20 02:40:23 von
Beiträge: 34
ID: 1.286.763
ID: 1.286.763
Aufrufe heute: 0
Gesamt: 3.638
Gesamt: 3.638
Aktive User: 0
ISIN: US14817C1071 · WKN: A2PGL8 · Symbol: PX91
20,250
EUR
+4,52 %
+0,875 EUR
Letzter Kurs 25.04.24 Tradegate
Neuigkeiten
15.04.24 · globenewswire  |
25.03.24 · globenewswire |
04.03.24 · globenewswire |
28.02.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,000 | +25,00 | |
| 6,0000 | +25,00 | |
| 0,7113 | +21,90 | |
| 56,69 | +20,00 | |
| 0,6400 | +18,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7603 | -15,21 | |
| 9,7200 | -19,60 | |
| 4,0000 | -27,27 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 |
Feedback
Ich bin mit einer kleinen Posi dabei! 
Link zur HP: http://www.paintrials.com/
Pain Therapeutics Awarded $3.2 Million NIH Grant to Study Alzheimer’s Disease
GlobeNewswire•August 15, 2018
– NIH Grant will Support Clinical Testing of PTI-125 –
– Initiation of Phase II Study Expected Q4 2018 –
AUSTIN, Texas, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, today announced that the National Institutes of Health (NIH) has awarded the Company a $3.2 million clinical research grant to support a Phase II study with PTI-125, the Company’s drug candidate to treat Alzheimer’s disease. Pain Therapeutics expects to initiate the study in Q4 2018.
"We are once again grateful to the NIH for its support of our clinical program around PTI-125," said Remi Barbier, President & CEO of Pain Therapeutics. “There is a profound need to develop new drugs for patients with Alzheimer’s. NIH has long been a champion of innovative new science that stands up to rigorous, peer-reviewed evaluation and that has potential to benefit human health in areas of unmet needs, such as Alzheimer's."
The NIH's National Institute on Aging awarded this clinical research grant to Pain Therapeutics following an in-depth, peer-reviewed evaluation of PTI-125 for scientific and technical merit.
About PTI-125
Pain Therapeutics believes its program in Alzheimer’s has game-changing characteristics. Its lead drug candidate, PTI-125, is a small molecule that has a unique mechanism of action for treating Alzheimer’s disease. The underlying science for PTI-125 is published in prestigious technical journals, including Journal of Neuroscience, Neurobiology of Aging, and Neuroimmunology and Neuroinflammation, with additional technical publications pending. The Company is also waiting to hear back from the NIH regarding a second research grant application to support PTI-125.
The Company’s other asset in Alzheimer’s is a simple blood test, called PTI-125DX, to detect or confirm whether a person has Alzheimer’s disease, even years before symptoms appear. An early diagnosis of Alzheimer's could allow treatment to start sooner, optimize treatment options for each individual and improve chances to slow or halt the disease.
About Alzheimer's Disease
Alzheimer’s Disease (AD) is a progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. There is no approved drug therapy to reverse, or even halt, the course of AD.
Strategic Reorganization Expected to be Announced Shortly
Pain Therapeutics has initiated a strategic reorganization to align its resources on advancing its drug and diagnostic assets in Alzheimer’s disease. Full details of this reorganization plan, including details of its planned Phase II study in Alzheimer’s, specific milestones and measures of clinical progress, will be shared with the public via conference call within weeks, after the reorganization is finalized.
About Pain Therapeutics, Inc.
Pain Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel drugs. The FDA has not yet established the safety or efficacy of any of our drug candidates. For more information, please visit www.paintrials.com.
https://finance.yahoo.com/news/pain-therapeutics-awarded-3-2…
GlobeNewswire•August 15, 2018
– NIH Grant will Support Clinical Testing of PTI-125 –
– Initiation of Phase II Study Expected Q4 2018 –
AUSTIN, Texas, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, today announced that the National Institutes of Health (NIH) has awarded the Company a $3.2 million clinical research grant to support a Phase II study with PTI-125, the Company’s drug candidate to treat Alzheimer’s disease. Pain Therapeutics expects to initiate the study in Q4 2018.
"We are once again grateful to the NIH for its support of our clinical program around PTI-125," said Remi Barbier, President & CEO of Pain Therapeutics. “There is a profound need to develop new drugs for patients with Alzheimer’s. NIH has long been a champion of innovative new science that stands up to rigorous, peer-reviewed evaluation and that has potential to benefit human health in areas of unmet needs, such as Alzheimer's."
The NIH's National Institute on Aging awarded this clinical research grant to Pain Therapeutics following an in-depth, peer-reviewed evaluation of PTI-125 for scientific and technical merit.
About PTI-125
Pain Therapeutics believes its program in Alzheimer’s has game-changing characteristics. Its lead drug candidate, PTI-125, is a small molecule that has a unique mechanism of action for treating Alzheimer’s disease. The underlying science for PTI-125 is published in prestigious technical journals, including Journal of Neuroscience, Neurobiology of Aging, and Neuroimmunology and Neuroinflammation, with additional technical publications pending. The Company is also waiting to hear back from the NIH regarding a second research grant application to support PTI-125.
The Company’s other asset in Alzheimer’s is a simple blood test, called PTI-125DX, to detect or confirm whether a person has Alzheimer’s disease, even years before symptoms appear. An early diagnosis of Alzheimer's could allow treatment to start sooner, optimize treatment options for each individual and improve chances to slow or halt the disease.
About Alzheimer's Disease
Alzheimer’s Disease (AD) is a progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. There is no approved drug therapy to reverse, or even halt, the course of AD.
Strategic Reorganization Expected to be Announced Shortly
Pain Therapeutics has initiated a strategic reorganization to align its resources on advancing its drug and diagnostic assets in Alzheimer’s disease. Full details of this reorganization plan, including details of its planned Phase II study in Alzheimer’s, specific milestones and measures of clinical progress, will be shared with the public via conference call within weeks, after the reorganization is finalized.
About Pain Therapeutics, Inc.
Pain Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel drugs. The FDA has not yet established the safety or efficacy of any of our drug candidates. For more information, please visit www.paintrials.com.
https://finance.yahoo.com/news/pain-therapeutics-awarded-3-2…
Trading Spotlight
Pain Therapeutics Announces Closing of $11.3 Million Registered Direct Offering
GlobeNewswire•August 17, 2018
AUSTIN, Texas, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, today announced the closing of its previously announced registered direct offering of 8,860,778 shares of its common stock, which was priced at-the-market at a purchase price of $1.15 per share, for gross proceeds of approximately $10.19 million.
Additionally, Pain Therapeutics issued unregistered warrants to purchase up to 8,860,778 shares of its common stock, at a purchase price of $0.125 per warrant, for gross proceeds of approximately $1.11 million. The warrants have an exercise price of $1.25 per share of common stock, are exercisable immediately and will expire two and one-half years from the issuance date.
The net proceeds of the offering are estimated to be approximately $10.3 million, after deducting placement agent fees and other estimated offering expenses. Pain Therapeutics intends to use the net proceeds from this offering for drug development and general corporate purposes and for other working capital and general corporate purposes.
The shares of common stock (but not the warrants or the shares of common stock underlying the warrants) were offered by Pain Therapeutics pursuant to a "shelf" registration statement on Form S-3 that was originally filed on April 14, 2017 and declared effective by the Securities and Exchange Commission ("SEC") on July 31, 2017 and the base prospectus contained therein (File No. 333-217319). The offering of the shares of common stock was made only by means of a prospectus supplement that forms a part of the registration statement.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
A final prospectus supplement and accompanying base prospectus relating to the shares of common stock was filed with the SEC. Copies of the final prospectus supplement and accompanying base prospectus may be obtained on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at placements@hcwco.com.
The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Pain Therapeutics, Inc.
Pain Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel drugs. The FDA has not yet established the safety or efficacy of any of our drug candidates. For more information, please visit www.paintrials.com.
https://finance.yahoo.com/news/pain-therapeutics-announces-c…
GlobeNewswire•August 17, 2018
AUSTIN, Texas, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, today announced the closing of its previously announced registered direct offering of 8,860,778 shares of its common stock, which was priced at-the-market at a purchase price of $1.15 per share, for gross proceeds of approximately $10.19 million.
Additionally, Pain Therapeutics issued unregistered warrants to purchase up to 8,860,778 shares of its common stock, at a purchase price of $0.125 per warrant, for gross proceeds of approximately $1.11 million. The warrants have an exercise price of $1.25 per share of common stock, are exercisable immediately and will expire two and one-half years from the issuance date.
The net proceeds of the offering are estimated to be approximately $10.3 million, after deducting placement agent fees and other estimated offering expenses. Pain Therapeutics intends to use the net proceeds from this offering for drug development and general corporate purposes and for other working capital and general corporate purposes.
The shares of common stock (but not the warrants or the shares of common stock underlying the warrants) were offered by Pain Therapeutics pursuant to a "shelf" registration statement on Form S-3 that was originally filed on April 14, 2017 and declared effective by the Securities and Exchange Commission ("SEC") on July 31, 2017 and the base prospectus contained therein (File No. 333-217319). The offering of the shares of common stock was made only by means of a prospectus supplement that forms a part of the registration statement.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
A final prospectus supplement and accompanying base prospectus relating to the shares of common stock was filed with the SEC. Copies of the final prospectus supplement and accompanying base prospectus may be obtained on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at placements@hcwco.com.
The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Pain Therapeutics, Inc.
Pain Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel drugs. The FDA has not yet established the safety or efficacy of any of our drug candidates. For more information, please visit www.paintrials.com.
https://finance.yahoo.com/news/pain-therapeutics-announces-c…
Nicht schlecht für einen Freitag!
Hört sich ja intessant an.
Zumindest für ‘nen Zock zum Beginn der Studie im letzten Quartal des Jahres. Wird bestimmt für Aufmerksamkeit sorgen. Wobei es natürlich nicht die 1. Biotech-Firma ist, die in Phase II mit einem Alzheimer-Medi geht...
Weiß jemand, warum der Kurs im Juni so eingeknickt ist? Schlechte Studiendaten mit dem Medi in einer anderen Indikation?
Zumindest für ‘nen Zock zum Beginn der Studie im letzten Quartal des Jahres. Wird bestimmt für Aufmerksamkeit sorgen. Wobei es natürlich nicht die 1. Biotech-Firma ist, die in Phase II mit einem Alzheimer-Medi geht...
Weiß jemand, warum der Kurs im Juni so eingeknickt ist? Schlechte Studiendaten mit dem Medi in einer anderen Indikation?
Antwort auf Beitrag Nr.: 58.664.712 von Stoxtrayder am 10.09.18 21:27:07Pain hat die Zulassung für REMOXY nicht bekommen! 
Ohwe, hab ich’s mir doch gedacht... ;-)
Immer wieder lustig, wie manche Biotechs nach gescheiterten Studien ihrer Medis versuchen, urplötzlich eine andere Indikation (warum nicht mal mit Alzheimer versuchen...?!) damit behandeln möchten. Bei meinen Depotleichen wie iBio & Tonix war’s ähnlich...
Allein die Homepage ist schon eine Zumutung.
Immer wieder lustig, wie manche Biotechs nach gescheiterten Studien ihrer Medis versuchen, urplötzlich eine andere Indikation (warum nicht mal mit Alzheimer versuchen...?!) damit behandeln möchten. Bei meinen Depotleichen wie iBio & Tonix war’s ähnlich...
Allein die Homepage ist schon eine Zumutung.
Antwort auf Beitrag Nr.: 58.664.760 von Lucky72 am 10.09.18 21:34:22Ist eben nix für schwache Nerven! 
Ich finde es nur gruselig wie viel Steuern ich bezahlen muß wenn ich verkaufe!
Ich finde es nur gruselig wie viel Steuern ich bezahlen muß wenn ich verkaufe!
PRESS RELEASE
<< Back
Pain Therapeutics Announces Investor Call to Provide Strategic Update
Call to be Held on Thursday, October 4th, 10:00 AM Eastern Time
AUSTIN, Texas, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that it will host a live conference call to provide a strategic update regarding its business, its science and its pipeline. The call is scheduled to be held Thursday, October 4th at 10 AM Eastern time, 9 AM Central time.
The audio presentation will be available via teleconference, which can be accessed by dialing (877) 407-4018 or (201) 689-8471 for international callers. A toll-free replay will be available at (844) 512-2921, or (412) 317-6671 for international callers, using the conference ID code: 13683822
The Company’s presentation will be available live via webcast and conference call. To listen to the webcast and view the accompanying slide presentation, please go to the Company’s website at http://www.paintrials.com/ and click on the webcast icon at least 15 minutes before the presentation is to begin to register. If you are unable to listen to the live webcast, please access http://www.paintrials.com/ at any time within seven days to listen to a replay of the webcast.
About Pain Therapeutics, Inc.
Pain Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel drugs. The Company believes its research program in Alzheimer’s disease has game-changing characteristics. Its lead drug candidate, PTI-125, is a small molecule with a unique mechanism of action to treat Alzheimer’s disease. The underlying science for PTI-125 is published in prestigious peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, and Neuroimmunology and Neuroinflammation, and benefits from several peer-reviewed research grant awards from the National Institutes of Health (NIH).
The Company is also developing a blood test, called PTI-125DX, to detect Alzheimer’s disease, possibly years before symptoms appear. An early diagnosis of Alzheimer's could allow treatment to start sooner, optimize treatment options for each individual and improve chances to slow or halt the disease.
Last, the Company also has an NDA-stage drug asset, REMOXY, for severe chronic pain, which is currently held up at the U.S. Food and Drug Administration (FDA). The FDA has not yet established the safety or efficacy of any of our drug candidates. For more information, please visit www.paintrials.com.
http://investor.paintrials.com/news-releases/news-release-de…
<< Back
Pain Therapeutics Announces Investor Call to Provide Strategic Update
Call to be Held on Thursday, October 4th, 10:00 AM Eastern Time
AUSTIN, Texas, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that it will host a live conference call to provide a strategic update regarding its business, its science and its pipeline. The call is scheduled to be held Thursday, October 4th at 10 AM Eastern time, 9 AM Central time.
The audio presentation will be available via teleconference, which can be accessed by dialing (877) 407-4018 or (201) 689-8471 for international callers. A toll-free replay will be available at (844) 512-2921, or (412) 317-6671 for international callers, using the conference ID code: 13683822
The Company’s presentation will be available live via webcast and conference call. To listen to the webcast and view the accompanying slide presentation, please go to the Company’s website at http://www.paintrials.com/ and click on the webcast icon at least 15 minutes before the presentation is to begin to register. If you are unable to listen to the live webcast, please access http://www.paintrials.com/ at any time within seven days to listen to a replay of the webcast.
About Pain Therapeutics, Inc.
Pain Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel drugs. The Company believes its research program in Alzheimer’s disease has game-changing characteristics. Its lead drug candidate, PTI-125, is a small molecule with a unique mechanism of action to treat Alzheimer’s disease. The underlying science for PTI-125 is published in prestigious peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, and Neuroimmunology and Neuroinflammation, and benefits from several peer-reviewed research grant awards from the National Institutes of Health (NIH).
The Company is also developing a blood test, called PTI-125DX, to detect Alzheimer’s disease, possibly years before symptoms appear. An early diagnosis of Alzheimer's could allow treatment to start sooner, optimize treatment options for each individual and improve chances to slow or halt the disease.
Last, the Company also has an NDA-stage drug asset, REMOXY, for severe chronic pain, which is currently held up at the U.S. Food and Drug Administration (FDA). The FDA has not yet established the safety or efficacy of any of our drug candidates. For more information, please visit www.paintrials.com.
http://investor.paintrials.com/news-releases/news-release-de…
2.90+1.94 (+200.55%)
At close: 4:00PM EDT
und keiner bekommt es mit!
Was für "Loser"!
At close: 4:00PM EDT
und keiner bekommt es mit!
Was für "Loser"!
Antwort auf Beitrag Nr.: 58.864.512 von Lucky72 am 03.10.18 22:37:53Schöne Präsentation...
Wenn das tatsächlich eintrifft.....
https://seekingalpha.com/article/4210117-pain-therapeutics-p…
Wenn das tatsächlich eintrifft.....
https://seekingalpha.com/article/4210117-pain-therapeutics-p…
Ich hab nochmal 2k nachgelegt
Antwort auf Beitrag Nr.: 58.995.465 von Lucky72 am 18.10.18 17:56:17Pain Therapeutics, valued at about $17 million, said it would now initiate a strategic reorganization to focus on its Alzheimer's disease treatments and diagnostic products.
Antwort auf Beitrag Nr.: 58.995.465 von Lucky72 am 18.10.18 17:56:17Quelle - Reuters.com
Pain Therapeutics Invites you to Join a Conference Call on Third Quarter 2018 Financial Results
GlobeNewswire•October 23, 2018
AUSTIN, Texas, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, announced today it will release third quarter 2018 financial results, and hold a conference call with a Q&A session, on Monday, October 29, 2018 at 4:30 p.m. Eastern Time.
The Company’s conference call can be accessed by dialing toll-free (877) 407-4018 (or 201 689-8471 for international callers). A replay will be available toll-free at (844) 512-2921, (or 412 317-6671 for international callers), using the conference ID code 13684539.
To listen to the Company’s webcast, please go to http://www.paintrials.com/ and click on “News”, then “Event & Presentations” to register. You may access http://www.paintrials.com/ at any time through Monday, November 5th, 2018, for a replay of the webcast for this conference call.
About the Company’s Neuroprotection Program
Our lead drug candidate, PTI-125, is a small molecule with a unique mechanism of action for treating Alzheimer’s disease (“AD”). We expect to initiate a Phase IIa study with PTI-125 in AD in Q4 2018.
The underlying science for PTI-125 is published in prestigious peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, and Neuroimmunology and Neuroinflammation, and benefits from several peer-reviewed research grant awards from the NIH.
We are also developing a blood-based test, called PTI-125Dx, to detect whether a person has Alzheimer’s disease, possibly years before any symptoms appear. An early diagnosis of AD could optimize treatment options and empower physicians and patients to slow or halt the disease.
About Alzheimer's Disease
Alzheimer’s Disease (AD) is a progressive brain disorder that destroys memory and thinking skills. Eventually, a person with AD may be unable to carry out even the simplest tasks. There is a profound and timely need to develop new drugs for Alzheimer’s. Currently, there are no drug therapies to halt Alzheimer’s, much less reverse its course.
About Pain Therapeutics, Inc.
We develop proprietary drugs and diagnostics that offer significant improvements to patients and physicians. Our expertise consists of developing new products and guiding these through various regulatory and development pathways in preparation for their eventual commercialization. The FDA has not yet established the safety or efficacy of our product candidates.
GlobeNewswire•October 23, 2018
AUSTIN, Texas, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, announced today it will release third quarter 2018 financial results, and hold a conference call with a Q&A session, on Monday, October 29, 2018 at 4:30 p.m. Eastern Time.
The Company’s conference call can be accessed by dialing toll-free (877) 407-4018 (or 201 689-8471 for international callers). A replay will be available toll-free at (844) 512-2921, (or 412 317-6671 for international callers), using the conference ID code 13684539.
To listen to the Company’s webcast, please go to http://www.paintrials.com/ and click on “News”, then “Event & Presentations” to register. You may access http://www.paintrials.com/ at any time through Monday, November 5th, 2018, for a replay of the webcast for this conference call.
About the Company’s Neuroprotection Program
Our lead drug candidate, PTI-125, is a small molecule with a unique mechanism of action for treating Alzheimer’s disease (“AD”). We expect to initiate a Phase IIa study with PTI-125 in AD in Q4 2018.
The underlying science for PTI-125 is published in prestigious peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, and Neuroimmunology and Neuroinflammation, and benefits from several peer-reviewed research grant awards from the NIH.
We are also developing a blood-based test, called PTI-125Dx, to detect whether a person has Alzheimer’s disease, possibly years before any symptoms appear. An early diagnosis of AD could optimize treatment options and empower physicians and patients to slow or halt the disease.
About Alzheimer's Disease
Alzheimer’s Disease (AD) is a progressive brain disorder that destroys memory and thinking skills. Eventually, a person with AD may be unable to carry out even the simplest tasks. There is a profound and timely need to develop new drugs for Alzheimer’s. Currently, there are no drug therapies to halt Alzheimer’s, much less reverse its course.
About Pain Therapeutics, Inc.
We develop proprietary drugs and diagnostics that offer significant improvements to patients and physicians. Our expertise consists of developing new products and guiding these through various regulatory and development pathways in preparation for their eventual commercialization. The FDA has not yet established the safety or efficacy of our product candidates.
Antwort auf Beitrag Nr.: 59.077.865 von Lucky72 am 28.10.18 16:41:52Ähnliches Spiel wie bei Auris?
Antwort auf Beitrag Nr.: 59.078.444 von Vogelnarr am 28.10.18 19:00:44Und es geht bergab... ich hav
Antwort auf Beitrag Nr.: 59.485.215 von Vogelnarr am 20.12.18 22:23:45Ich hab kein Glück...
Antwort auf Beitrag Nr.: 59.485.221 von Vogelnarr am 20.12.18 22:24:14Nice plus 60%🙂
Antwort auf Beitrag Nr.: 59.485.221 von Vogelnarr am 20.12.18 22:24:14Kann man ruhig 50% oder mehr verkaufen
Wow, was geht denn hier ab?
Läuft😊😊🚀
Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s Disease
Tue January 28, 2020 8:15 AM|GlobeNewswire|About: SAVA
GlobeNewswire
AUSTIN, Texas, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it has initiated dosing for the last patient in a Phase 2b study of PTI-125. This completes patient enrollment in a randomized, double-blind, placebo-controlled, Phase 2b study of PTI-125, Cassava Sciences’ investigational drug to treat Alzheimer’s disease. A total of 64 patients were enrolled in this study and top-line results are expected mid-year 2020.
https://seekingalpha.com/pr/17761007-cassava-sciences-announ…
Tue January 28, 2020 8:15 AM|GlobeNewswire|About: SAVA
GlobeNewswire
AUSTIN, Texas, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it has initiated dosing for the last patient in a Phase 2b study of PTI-125. This completes patient enrollment in a randomized, double-blind, placebo-controlled, Phase 2b study of PTI-125, Cassava Sciences’ investigational drug to treat Alzheimer’s disease. A total of 64 patients were enrolled in this study and top-line results are expected mid-year 2020.
https://seekingalpha.com/pr/17761007-cassava-sciences-announ…
Antwort auf Beitrag Nr.: 62.509.154 von clearasil am 28.01.20 15:00:02https://seekingalpha.com/article/4317789-cassava-sciences-an…
Cassava’s Drug Discovery
"SAVA has two products in its pipeline for which it owns proprietary, worldwide rights, without royalty or milestone obligations.
PTI-125 is an oral, small molecule drug that is now in the middle of a Phase 2(B) study, with results expected by mid-2020. It receives long-term scientific & financial support from the National Institute of Health (NIH)
PTI-125Dx is an Alzheimer’s detection (diagnostic) system. It is currently undergoing clinical testing.
Both products will enter the pivotal (or clinical) trial phase in 2021, and after positive results will be ready to be marketed.
Currently, Alzheimer’s can be definitively diagnosed only after death. Therefore, if the PT-125Dx’s clinical tests are successful, along with a successful PT-125, this will imply bumper prospects for the company.
For SAVA, its current results do not matter. What matters is the success of their trials. The progress of whatever is happening is known only to the insiders."
"Between 26 Sep 2019 and 31 Dec 2019, SAVA insiders bought over 700,000 shares between $1.02 and $5.53.
The last purchase was by Barbier Remi (CEO) at $5.53. The largest purchase of 423,000 shares was made by a director at $2.20."
Cassava’s Drug Discovery
"SAVA has two products in its pipeline for which it owns proprietary, worldwide rights, without royalty or milestone obligations.
PTI-125 is an oral, small molecule drug that is now in the middle of a Phase 2(B) study, with results expected by mid-2020. It receives long-term scientific & financial support from the National Institute of Health (NIH)
PTI-125Dx is an Alzheimer’s detection (diagnostic) system. It is currently undergoing clinical testing.
Both products will enter the pivotal (or clinical) trial phase in 2021, and after positive results will be ready to be marketed.
Currently, Alzheimer’s can be definitively diagnosed only after death. Therefore, if the PT-125Dx’s clinical tests are successful, along with a successful PT-125, this will imply bumper prospects for the company.
For SAVA, its current results do not matter. What matters is the success of their trials. The progress of whatever is happening is known only to the insiders."
"Between 26 Sep 2019 and 31 Dec 2019, SAVA insiders bought over 700,000 shares between $1.02 and $5.53.
The last purchase was by Barbier Remi (CEO) at $5.53. The largest purchase of 423,000 shares was made by a director at $2.20."
https://seekingalpha.com/pr/17775168-cassava-sciences-announ…
Key results published from the Phase 2a study include:
Total tau (T-tau) decreased 20% (p<0.001)
Phosphorylated tau (P-tau) decreased 34% (p<0.0001)
Neurofilament light chain (NfL), a marker for neurodegeneration, decreased 22% (p<0.0001)
Neurogranin, a marker for cognitive decline, decreased 32% (p<0.0001)
Neuroinflammatory marker YKL-40, an indicator of microglial activation, decreased 9% (p<0.0001)
Proinflammatory Interleukin 6 (IL-6) decreased 14% (p<0.0001)
Proinflammatory Interleukin 1 beta (IL-1β) decreased 11% (p<0.0001)
Proinflammatory Tumor Necrosis Factor alpha (TNFα) decreased 5% (p<0.001)
The ratio of CSF P-tau to Aβ42, a widely accepted biochemical value of Alzheimer’s disease, improved in all patients (p<0.001)
"Nadav Friedmann, MD, PhD, Chief Medical Officer at Cassava Sciences commented, “We are pleased to share these study results in JPAD. This publication provides clinical insights into how our lead drug candidate, PTI-125, could make an important difference for patients living with Alzheimer’s disease. In this study, PTI-125 reduced multiple biomarkers of Alzheimer’s disease, including neurodegeneration and neuroinflammation. To our knowledge, no other drug has shown such effects in Alzheimer’s patients.”
Published results from this study demonstrate that biomarkers of Alzheimer’s disease pathology (P-tau, total tau and Aβ42), neurodegeneration (NfL and neurogranin) and neuroinflammation (YKL-40, IL-6, IL-1β and TNFα) improved significantly after 28 days of treatment with PTI-125. Biomarker reductions were at least p< 0.001 by paired t-test. Biomarkers effects were seen in all patients in both cerebrospinal fluid (CSF) and plasma. PTI-125 was safe and well tolerated, with no observable drug-related adverse events.
Lindsay H. Burns, PhD, VP Neuroscience at Cassava Sciences, added, “This publication supports PTI-125 as a new and potentially disease-modifying drug treatment for Alzheimer’s disease. Significant improvements observed across multiple biomarkers imply a slower rate of neurodegeneration or a suppression of disease processes. These treatment effects are consistent with the drug’s mechanism of action and over ten years of basic research and preclinical data.”
Key results published from the Phase 2a study include:
Total tau (T-tau) decreased 20% (p<0.001)
Phosphorylated tau (P-tau) decreased 34% (p<0.0001)
Neurofilament light chain (NfL), a marker for neurodegeneration, decreased 22% (p<0.0001)
Neurogranin, a marker for cognitive decline, decreased 32% (p<0.0001)
Neuroinflammatory marker YKL-40, an indicator of microglial activation, decreased 9% (p<0.0001)
Proinflammatory Interleukin 6 (IL-6) decreased 14% (p<0.0001)
Proinflammatory Interleukin 1 beta (IL-1β) decreased 11% (p<0.0001)
Proinflammatory Tumor Necrosis Factor alpha (TNFα) decreased 5% (p<0.001)
The ratio of CSF P-tau to Aβ42, a widely accepted biochemical value of Alzheimer’s disease, improved in all patients (p<0.001)
"Nadav Friedmann, MD, PhD, Chief Medical Officer at Cassava Sciences commented, “We are pleased to share these study results in JPAD. This publication provides clinical insights into how our lead drug candidate, PTI-125, could make an important difference for patients living with Alzheimer’s disease. In this study, PTI-125 reduced multiple biomarkers of Alzheimer’s disease, including neurodegeneration and neuroinflammation. To our knowledge, no other drug has shown such effects in Alzheimer’s patients.”
Published results from this study demonstrate that biomarkers of Alzheimer’s disease pathology (P-tau, total tau and Aβ42), neurodegeneration (NfL and neurogranin) and neuroinflammation (YKL-40, IL-6, IL-1β and TNFα) improved significantly after 28 days of treatment with PTI-125. Biomarker reductions were at least p< 0.001 by paired t-test. Biomarkers effects were seen in all patients in both cerebrospinal fluid (CSF) and plasma. PTI-125 was safe and well tolerated, with no observable drug-related adverse events.
Lindsay H. Burns, PhD, VP Neuroscience at Cassava Sciences, added, “This publication supports PTI-125 as a new and potentially disease-modifying drug treatment for Alzheimer’s disease. Significant improvements observed across multiple biomarkers imply a slower rate of neurodegeneration or a suppression of disease processes. These treatment effects are consistent with the drug’s mechanism of action and over ten years of basic research and preclinical data.”
Antwort auf Beitrag Nr.: 62.645.878 von clearasil am 11.02.20 14:52:29Heute -80%.
Wow... warum das denn?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,16 | |
| +0,66 | |
| +1,46 | |
| -0,07 | |
| +0,67 | |
| +8,88 | |
| -0,15 | |
| +0,65 | |
| +0,43 | |
| -0,46 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 249 | ||
| 95 | ||
| 93 | ||
| 82 | ||
| 79 | ||
| 45 | ||
| 35 | ||
| 33 | ||
| 32 | ||
| 31 |
| Zeit | Titel |
|---|---|
| 10.04.24 |